Access to generic antiretrovirals: Inequality, intellectual property law, and international trade agreements

Cadernos de Saude Publica

Volumn 23, Issue SUPPL. 1, 2007, Pages

  Castro, Arachu ^a   Westerhaus, Michael ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acquired immunodeficiency syndrome; Antiretroviral agents; Drug industry; Generic drugs

Indexed keywords

ANTIRETROVIRUS AGENT; GENERIC DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COMMERCIAL PHENOMENA; DEVELOPING COUNTRY; DRUG INDUSTRY; HEALTH; HEALTH CARE DELIVERY; HUMAN; INTERNATIONAL COOPERATION; LEGAL ASPECT; PATENT; SOCIOECONOMICS; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-RETROVIRAL AGENTS; COMMERCE; DEVELOPING COUNTRIES; DRUG INDUSTRY; DRUGS, GENERIC; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTELLECTUAL PROPERTY; INTERNATIONAL COOPERATION; PATENTS AS TOPIC; SOCIOECONOMIC FACTORS; UNITED STATES; WORLD HEALTH;

EID: 33847062117     PISSN: 0102311X     EISSN: 16784464     Source Type: Journal    
DOI: 10.1590/S0102-311X2007001300010     Document Type: Article

References (73)

1. Westerhaus M, Castro A. How do intellectual property law and international trade agreements affect access to antiretroviral therapy. PLoS Med 2006; 3:e332.
2. World Intellectual Property Organization. Paris convention for the protection of industrial property. http://www.wipo.int/clea/docs/en/wo/wo020en. htm (accessed on Nov/2004).
3. World Trade Organization. Members and observers. http://www.wto.org/ english/thewto_e/whatis_e/tif_e/org6_e.htm (accessed on 25/Jan/2005).
4. World Trade Organization. Declaration on the TRIPS agreement and public health. http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm (accessed on 12/Oct/2004).
5. Loff B. No agreement reached in talks on access to cheap drugs. Lancet 2002; 360:1951.
6. United Nations. List of least developed countries. http://www.un.org/ special-rep/ohrlls/ldc/list.htm (accessed on Jan/2005).
7. 't Hoen EFM. TRIPS, pharmaceutical patents and access to essential medicines: Seattle, Doha, and beyond. In: Agence Nationale de Recherches sur le Sida, editors. Economics of AIDS and access to HIV/AIDS care in developing countries: issues and challenges. Paris: Agence Nationale de Recherches sur le Sida; 2003. p. 39-67.
8. Oliveira MA, Bermudez JA, Chaves GC, Velasquez G. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health? Bull World Health Organ 2004; 82:815-21.
9. Adelman K. Praise for piracy? The Washington Times 2005; 9 may.
10. Kaiser Daily HIV/AIDS Report. Drug access/Brazil requests voluntary licensing for AIDS drugs to treat more patients, reduce costs of importing patented drugs. http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint= 1&DR_ID=28706 (accessed on 21/Nov/2005).
11. Consumer Project on Technology. Recent health-related compulsory licenses and disputes. http://www.cptech.org/ip/health/cl/recent-examples.html (accessed on May/2005).
12. Joint United Nations Programme on HIV/AIDS. AIDS epidemic update december 2005. Geneva: Joint United Nations Programme on HIV/AIDS; 2005.
13. Centers for Disease Control and Prevention. Global AIDS Program: countries - South Africa. http://www.cdc.gov/nchstp/od/gap/countries/ south_africa.htm (accessed on Nov/2004).
14. World Bank. Long term economic impact of HIV/AIDS more damaging than previously thought. http://web.worldbank.org/WBSITE/EXTERNAL/NEWS/0,,contentMDK: 20120894~menuPK:34463~pagePK:34370~piPK:34424~theSitePK:4607,00.html (accessed on 19/Sep/2004).
15. Farmer P, Leandre F, Mukherjee JS, Claude M, Nevil P, Smith-Fawzi MC, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet 2001; 358:404-9.
16. World Health Organization. Progress on global access to HIV antiretroviral therapy: a report on "3 by 5" and beyond. http://www.who.int/hiv/fullreport_en_highres.pdf (accessed on 03/Apr/2006).
17. World Health Organization. "3 by 5" progress report - december 2004. Progress in numbers. http://www.who.int/3by5/en/numbers.pdf (accessed on May/2005).
18. World Health Organization. The WHO model list of essential medicines: 13th model list of essential medicines. http://www.who.int/medicines/ organization/par/edl/eml.shtml (accessed on Jan/2005).
19. amFAR AIDS Research. TREAT Asia special report: expanded availability of HIV/AIDS drugs in Asia creates urgent need for trained doctors. http://web.amfar.org/treatment/news/TADoc7.pdf (accessed on 21/Nov/2005).
20. Shaw DG. Strike a balance on product patents: there are perverse incentives in the current system. http://lists.essential.org/pipermail/iphealth/ 2004-December/007314.html (accessed on Jan/2005).
21. Médecins Sans Frontières. Sources of affordable generic medicines drying up? India should ensure global access to medicines when amending its patent law. New York: Médecins Sans Frontières; 2005.
22. McNeil DG. India alters law on drug patents. New York Times 2005; 24 mar.
23. India's choice [Editorial]. New York Times 2005; 18 jan.
24. Kim J. WHO letter to India's health minister on patent legislation. http://www.cptech.org/ip/health/c/india/who12172004.html (accessed on Jan/2005).
25. Joint Action Committee Against Amendment of the Indian patents act: declaration. http://www.cptech.org/ip/health/c/india/ngodeclaration12292004.html (accessed on Jan/2005).
26. Pharmaceutical Research and Manufacturers of America. The issues: intellectual property. http://www.phrma.org/issues/intprop/ (accessed on Jan/2005).
27. Consumer Project on Technology. Additional notes on government role in the development of HIV/AIDS drugs. http://www.cptech.org/ip/health/aids/gov- role.html (accessed on Jan/2005).
28. August EM, Marongiu ME, Lin TS, Prusoff WH. Initial studies on the cellular pharmacology of 3′-deoxythymidin-2′-ene (d4T): a potent and selective inhibitor of human immunodeficiency virus. Biochem Pharmacol 1988; 37:4419-22.
29. Curtis J. Hunting down HIV. http://info.med.yale.edu/external/pubs/ ym_su98/cover/cov_hunting11.html (accessed on Jan/2005).
30. DeYoung K, Brubaker B. HIV drug price cut for some in Africa: protesters rallied outside Bristol-Myers's New York offices March 5 as a South African court heard AIDS drug issues. Washington Post 2001; 15 mar.
31. Angell M. The truth about the drug companies. New York: Random House; 2004.
32. Love J, Hubbard T. Make drugs affordable: replace TRIPs-plus by R&D-plus. Bridges 2004; 8:1-4.
33. Chien C. Cheap drugs at what price to innovation: does the compulsory licensing of pharmaceuticals hurt innovation? Berkeley Technol Law J 2003; 18:1-57.
34. Pecoul B, Chirac P, Trouiller P, Pinel J. Access to essential drugs in poor countries: a lost battle? JAMA 1999; 281:361-7.
35. Attaran A. How do patents and economic policies affect access to essential medicines in developing countries? Health Aff 2004; 23:155-66.
36. Attaran A, Gillespie-White L. Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa? JAMA 2001; 286:1886-92.
37. Dumoulin J, Flori Y-A, Vinard P, Borel T. World market strategies for drugs to fight AIDS. In: Agence Nationale de Recherches sur le Sida, editor. Economics of AIDS and access to HIV/AIDS care in developing countries: issues and challenges. Paris: Agence Nationale de Recherches sur le Sida; 2003. p. 213-44.
38. Lucchini S, Cisse B, Duran S, Cenival M, Comiti C, Gaudry M, et al. Decrease in prices of antiretroviral drugs for developing countries: from political "philanthropy" to regulated markets? In: Agence Nationale de Recherches sur le Sida, editor. Economics of AIDS and access to HIV/AIDS care in developing countries: issues and challenges. Paris: Agence Nationale de Recherches sur le Sida; 2003. p. 169-211.
39. Rosenberg T. Look at Brazil. New York Times 2001; 28 jan.
40. Stiglitz J. New trade pacts betray the poorest partners. New York Times 2004; 24 jul.
41. 't Hoen E. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. Chic J Int Law 2002; 3:27-48.
42. Coriat B, Dumoulin J, Flori Y-A, Barnett T, Souteyrand Y, Moatti J-P. Patents, generic drugs and the markets for antiretrovirals. In: Moatti J-P, Coriat B, Souteyrand Y, Barnett T, Dumoulin J, Flori Y-A, editors. Economics of AIDS and access to HIV/AIDS care in developing countries: issues and challenges. Paris: National Agency for AIDS Research; 2003. p. 27-37.
43. Kremer M, Glennerster R. Strong medicine: creating incentives for pharmaceutical research on neglected diseases. Princeton: Princeton University Press; 2004.
44. Médecins Sans Frontières. No consensus at the TRIPS council but a last opportunity to fix flaws in the TRIPS agreement. New York: Médecins Sans Frontières; 2003.
45. Médecins Sans Frontières. Access to medicines at risk across the globe: what to watch out for in the free trade agreements with the United States. http://www.accessmed-msf.org/documents/ftabriefingenglish.pdf (accessed on 21/Nov/2005).
46. Rosenberg M. Centam says trade pact stalled by medicine rules. Reuters Wire 2006; 11 jan.
47. Office of the United States Global AIDS Coordinator. The President's plan for AIDS Relief: U.S. Fiveyear global HIV/AIDS strategy. Washington DC: State Department; 2004.
48. Office of the United States Global AIDS Coordinator. Engendering bold leadership. The President's plan for emergency AIDS relief: first annual report to Congress. Washington DC: State Department; 2005.
49. Office of the United States Trade Representative. The Dominican Republic - Central America - United States Free Trade Agreement. http://www.ustr.gov/ Trade_Agreements/Bilateral/DR-CAFTA/DRCAFTA_Final_Texts/Section_Index.html (accessed on 12/Oct/2004).
50. Médecins Sans Frontières. Open letter to ministers of trade in countries negotiating the US-Andean Free Trade Agreement. http://www.accessmedmsf.org/prod/publications.asp?scntid=1692004101603& contenttype=PARA& (accessed on 15/Oct/2004).
51. Blustein P. U.S., Peru strike free-trade agreement. Washington Post 2005; 8 dec.
52. Office of the United States Trade Representative. Subject to legal review for accuracy, clarity, and consistency subject to authentication of English and Spanish versions. Draft 6 January 2006. Chapter sixteen. Intellectual property rights. http://www.ustr.gov/assets/Trade_Agreements/Bilateral/Peru_TPA/ Final_Texts/asset_upload_file509_8706.pdf (accessed on 01/Apr/2006).
53. Office of the United States Trade Representative. United States and Colombia conclude free trade agreement. www.ustr.gov/Document_Library/ Press_Releases/2006/February/ United_States_Colombia_Conclude_Free_Trade_Agreement.html (accessed on 01/Apr/2006).
54. Russell A. House Democrats criticize administration over IPR provisions in FTAS. http://lists.essential.org/pipermail/ip-health/2004-October/007018.html (accessed on Dec/2004).
55. Cohen D. Competition Commission finds pharmaceutical firms in contravention of the Competition Act. Beachhead media and investor relations. www.cptech.org/ip/health/sa/cc10162003.html (accessed on Dec/2004).
56. Galvão J. Access to antiretroviral drugs in Brazil. Lancet 2002; 360:1862-5.
57. Galvão J. A política brasileira de distribuição e produção de medicamentos anti-retrovirais: privilégio ou um direito? Cad Saúde Pública 2002; 18:213-9.
58. Teixeira PR, Vitória MA, Barcarola J. The Brazilian experience in providing universal access to antiretroviral therapy. In: Agence Nationale de Recherches sur le Sida, editor. Economics of AIDS and access to HIV/AIDS care in developing countries: issues and challenges. Paris: Agence Nationale de Recherches sur le Sida; 2003. p. 69-88.
59. BBC News. New anti-HIV drug deal for Brazil. http://news.bbc.co.uk/1/hi/ world/americas/3281683.stm (accessed on 12/Nov/2004).
60. Raghavan C. Health: assembly adopts new revised drug strategy. http://www.twnside.org.sg/title/assembly-cn.htm (accessed on Jan/2005).
61. World Health Organization. WHO to address trade and pharmaceuticals. http://www.who.int/inf-pr-1999/en/pr99-wha13.html (accessed Jan/2005).
62. World Health Organization. Revised drug strategy. http://www.who.int/gb/ ebwha/pdf_files/WHA54/ea5417.pdf (accessed Jan/2005).
63. World Health Organization. Scaling up treatment and care within a coordinated and comprehensive response to HIV/AIDS. Resolution WHA 57.14 of the 57th World Health http://www.who.int/gb/ebwha/pdf_files/WHA57/A57_R14-en.pdf (accessed on Jan/2005).
64. Bishops' Secretariat of Central America/Chairmen of the Domestic/International Policy Committees of the United States Conference of Catholic Bishops. Joint statement concerning the United States-Central American Free Trade Agreement (US-CAFTA). www.usccb.org (accessed on Jan/2005).
65. United Nations High Commission for Human Rights. US-Peru trade negotiations: special rapporteur on right to health reminds parties of human rights obligations. http://www.unhchr.ch/huricane/huricane.nsf/0 /35C240E546171AC1C1256EC800308A37?opendocument (accessed on 15/Oct/2004).
66. Consumer Project on Technology. Carta abierta al señor presidente de la República. http://www.cptech.org/ip/health/trade/andean/ ecuadorletter03232006.html (accessed on 01/Apr/2006).
67. Andrade C. Ecuador calls emergency to quell Indian protest. The Boston Globe 2006; 21 mar.
68. Daniel F. Guatemalan HIV patients slam new trade rules. http://www.alertnet.org/thenews/newsdesk/N30211004.htm (accessed on 01/Apr/2006).
69. Dickerson M, Iritani E. Trade accord with U.S. splits voters in Costa Rica. The Los Angeles Times 2006; 7 feb.
70. BBC News. Nobel laureate to lead Costa Rica. http://news.bbc.co.uk/1/hi/ world/americas/4773220.stm (accessed on 01/Apr/2006).
71. Morel CM, Acharya T, Broun D, Dangi A, Elias C, Ganguly NK, et al. Health innovation networks to help developing countries address neglected diseases. Science 2005; 309:401-4.
72. World Health Organization. Progress on global access to HIV antiretroviral therapy: an update on "3 by 5". Geneva: World Health Organization; 2005.
73. Kimball AM. The health of nations: happy birthday WTO. Lancet 2006; 367:188-90.